{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:45:48Z","timestamp":1782866748740,"version":"3.54.5"},"reference-count":68,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,26]],"date-time":"2024-09-26T00:00:00Z","timestamp":1727308800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100008322","name":"CSL Behring","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008322","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.jtha.2024.07.029","type":"journal-article","created":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T01:55:17Z","timestamp":1724378117000},"page":"3084-3096","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Gene therapy for people with hemophilia B: a proposed care delivery model in Italy"],"prefix":"10.1016","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4973-1317","authenticated-orcid":false,"given":"Giancarlo","family":"Castaman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4235-7166","authenticated-orcid":false,"given":"Giovanni","family":"Di Minno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6744-383X","authenticated-orcid":false,"given":"Paolo","family":"Simioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8078-8402","authenticated-orcid":false,"given":"Angelo Claudio","family":"Molinari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1641-6508","authenticated-orcid":false,"given":"Sergio","family":"Siragusa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1759-615X","authenticated-orcid":false,"given":"Erminia","family":"Baldacci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4685-7184","authenticated-orcid":false,"given":"Vincenzo","family":"La Mura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5009-9876","authenticated-orcid":false,"given":"Angelo","family":"Lupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0567-0260","authenticated-orcid":false,"given":"Enrico Ferri","family":"Grazzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7423-9864","authenticated-orcid":false,"given":"Flora","family":"Peyvandi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2024.07.029_bib1","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1111\/jth.12958","article-title":"Hemophilia B: molecular pathogenesis and mutation analysis","volume":"13","author":"Goodeve","year":"2015","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.029_bib2","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1111\/hae.14186","article-title":"Genetic causes of haemophilia in women and girls","volume":"27","author":"Miller","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib3","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1111\/jth.12672","article-title":"Factor IX and Rare Coagulation Disorders of the Scientific and Standardization Committee of the International Society on Thrombosis and Hemostasis. Definitions in hemophilia: communication from the SSC of the ISTH","volume":"12","author":"Blanchette","year":"2014","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.029_bib4","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJM200106073442307","article-title":"The hemophilias--from royal genes to gene therapy","volume":"344","author":"Mannucci","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.029_bib5","series-title":"Hemophilia B. Treasure Island (FL)","author":"Alshaikhli","year":"2023"},{"issue":"Suppl 2","key":"10.1016\/j.jtha.2024.07.029_bib6","first-page":"S11","article-title":"Young adults with hemophilia in the U.S.: demographics, comorbidities, and health status","volume":"90","author":"Curtis","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtha.2024.07.029_bib7","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1056\/NEJMe078098","article-title":"Prophylactic treatment for prevention of joint disease in hemophilia--cost versus benefit","volume":"357","author":"Roosendaal","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.029_bib8","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1080\/17474086.2018.1489719","article-title":"The benefits of prophylaxis in patients with hemophilia B","volume":"11","author":"Castaman","year":"2018","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2024.07.029_bib9","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/hae.14046","article-title":"WFH Guidelines for the Management of\u00a0Hemophilia panelists and co-authors. WFH guidelines for the management of hemophilia, 3rd edition","volume":"26","author":"Srivastava","year":"2020","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib10","doi-asserted-by":"crossref","first-page":"2313","DOI":"10.1056\/NEJMoa1305074","article-title":"Phase 3 study of recombinant factor IX Fc fusion protein in hemophilia B","volume":"369","author":"Powell","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.029_bib11","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","article-title":"Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial","volume":"127","author":"Santagostino","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.029_bib12","doi-asserted-by":"crossref","first-page":"3880","DOI":"10.1182\/blood-2014-05-573055","article-title":"Recombinant long-acting glycoPEGylated factor IX in hemophilia B: a multinational randomized phase 3 trial","volume":"124","author":"Collins","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.029_bib13","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1111\/jth.14778","article-title":"Long-term safety and efficacy of rIX-FP prophylaxis with extended dosing intervals up to 21 days in adults\/adolescents with hemophilia B","volume":"18","author":"Mancuso","year":"2020","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.029_bib14","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.2147\/DDDT.S236788","article-title":"Albumin-fusion recombinant FIX in the management of people with hemophilia B: an evidence-based review","volume":"16","author":"Pasca","year":"2022","journal-title":"Drug Des Devel Ther"},{"key":"10.1016\/j.jtha.2024.07.029_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.rpth.2023.100195","article-title":"Extended half-life factor IX prophylaxis up to every 21 days in hemophilia B: a longitudinal analysis of the efficacy and safety in selected adult patients","volume":"7","author":"Pabinger","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.029_bib16","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1186\/s13023-021-02152-1","article-title":"Clinical, humanistic, and economic burden of severe haemophilia B in adults receiving factor IX prophylaxis: findings from the CHESS II real-world burden of illness study in Europe","volume":"16","author":"Burke","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jtha.2024.07.029_bib17","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1182\/bloodadvances.2018020552","article-title":"The frequency of joint hemorrhages and procedures in nonsevere hemophilia A vs B","volume":"2","author":"Soucie","year":"2018","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.07.029_bib18","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1111\/hae.12533","article-title":"Adherence to prophylaxis is associated with better outcomes in moderate and severe haemophilia: results of a patient survey","volume":"21","author":"Krishnan","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib19","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/hae.14333","article-title":"Adherence to prophylaxis and its association with activation of self-management and treatment satisfaction","volume":"27","author":"Hoefnagels","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib20","doi-asserted-by":"crossref","first-page":"2112","DOI":"10.1111\/jth.15444","article-title":"Hemophilic arthropathy: current knowledge and future perspectives","volume":"19","author":"Gualtierotti","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.029_bib21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2018-07-820720","article-title":"Update on clinical gene therapy for hemophilia","volume":"133","author":"Perrin","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.029_bib22","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/hae.14807","article-title":"Towards achieving a haemophilia-free mind","volume":"29","author":"Hermans","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib23","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","article-title":"Hemophilia B gene therapy with a high-specific-activity factor IX variant","volume":"377","author":"George","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.029_bib24","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1056\/NEJMoa0904377","article-title":"X-linked thrombophilia with a mutant factor IX (factor IX Padua)","volume":"361","author":"Simioni","year":"2009","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.029_bib26","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1056\/NEJMoa2211644","article-title":"Gene therapy with etranacogene dezaparvovec for hemophilia B","volume":"388","author":"Pipe","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.029_bib27","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/17474086.2023.2276206","article-title":"Etranacogene dezaparvovec for the treatment of adult patients with severe and moderately severe hemophilia B","volume":"16","author":"Castaman","year":"2023","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.jtha.2024.07.029_bib28","doi-asserted-by":"crossref","first-page":"5671","DOI":"10.1182\/bloodadvances.2022008886","article-title":"Stable and durable factor IX levels in patients with hemophilia B over 3 years after etranacogene dezaparvovec gene therapy","volume":"7","author":"von Drygalski","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.07.029_bib29","first-page":"34","article-title":"Stable and durable factor IX levels over 4 years after etranacogene dezaparvovec gene therapy administration in a phase 2b trial in patients with haemophilia B [abstract]","volume":"30","author":"von Drygalski","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib30","doi-asserted-by":"crossref","first-page":"e265","DOI":"10.1016\/S2352-3026(24)00006-1","article-title":"Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE-B): 24-month post-hoc efficacy and safety data from a single-arm, multicentre, phase 3 trial","volume":"11","author":"Coppens","year":"2024","journal-title":"Lancet Haematol"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.07.029_bib31","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1182\/blood-2023-187624","volume":"142","author":"Pipe","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2024.07.029_bib32","first-page":"18","article-title":"First report of a long-term follow-up extension study 6 years after gene therapy with AMT-060 in adults with hemophilia B confirms safety and stable FIX expression and sustained reductions in factor IX use [abstract]","volume":"30","author":"Miesbach","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib33","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1111\/hae.14420","article-title":"Delivery of AAV-based gene therapy through haemophilia centres-A need for re-evaluation of infrastructure and comprehensive care: a joint publication of EAHAD and EHC","volume":"27","author":"Miesbach","year":"2021","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib34","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1111\/hae.14709","article-title":"Laying the foundations for gene therapy in Italy for patients with haemophilia A: a Delphi consensus study","volume":"29","author":"Castaman","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib35","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1111\/hae.14887","article-title":"Accreditation model of European Haemophilia Centres in the era of novel treatments and gene therapy","volume":"29","author":"Boban","year":"2023","journal-title":"Haemophilia"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.07.029_bib36","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1186\/s12913-017-2341-x","article-title":"The hub-and-spoke organization design: an avenue for serving patients well","volume":"17","author":"Elrod","year":"2017","journal-title":"BMC Health Serv Res"},{"key":"10.1016\/j.jtha.2024.07.029_bib37","doi-asserted-by":"crossref","first-page":"e86","DOI":"10.1111\/hae.14546","article-title":"Gene therapy of hemophilia: Hub centres should be haemophilia centres: a joint publication of EAHAD and EHC","volume":"28","author":"Miesbach","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib38","doi-asserted-by":"crossref","first-page":"767","DOI":"10.2147\/PPA.S239810","article-title":"The patient experience of gene therapy for hemophilia: qualitative interviews with trial patients","volume":"14","author":"Miesbach","year":"2020","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2024.07.029_bib39","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1111\/hae.14985","article-title":"Administration of gene therapy for haemophilia - the hub and spoke model and its regional differences and challenges","volume":"30","author":"Miesbach","year":"2024","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib40","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.1111\/hae.14440","article-title":"Implications of haemophilia gene therapy for the changing role of the multidisciplinary team","volume":"28","author":"Miesbach","year":"2022","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/s13023-022-02256-2","article-title":"The experiences of people with haemophilia and their families of gene therapy in a clinical trial setting: regaining control, the Exigency study","volume":"17","author":"Fletcher","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jtha.2024.07.029_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.blre.2020.100759","article-title":"Discussing investigational AAV gene therapy with hemophilia patients: a guide","volume":"47","author":"Sidonio","year":"2021","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2024.07.029_bib43","article-title":"Awareness of individual goals, preferences, and priorities of persons with severe congenital haemophilia A for a tailored shared decision-making approach to liver-directed gene therapy. A practical guideline","volume":"62","author":"Di","year":"2023","journal-title":"Blood Rev"},{"key":"10.1016\/j.jtha.2024.07.029_bib44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s13023-020-01555-w","article-title":"Optimizing language for effective communication of gene therapy concepts with hemophilia patients: a qualitative study","volume":"16","author":"Hart","year":"2021","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jtha.2024.07.029_bib45","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1186\/s13023-023-02977-y","article-title":"Educational needs of patients, families, and healthcare professionals to support the patient journey in haemophilia gene therapy in the UK","volume":"18","author":"Boyce","year":"2023","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.jtha.2024.07.029_bib46","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1111\/hae.13769","article-title":"How to discuss gene therapy for haemophilia? A patient and physician perspective","volume":"25","author":"Miesbach","year":"2019","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib47","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1111\/hae.14867","article-title":"Delivery of gene therapy in haemophilia treatment centres in the United States: practical aspects of preparedness and implementation","volume":"29","author":"Pipe","year":"2023","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/j.jhep.2022.11.014","article-title":"Liver-related aspects of gene therapy for haemophilia: call to action for collaboration between haematologists and hepatologists","volume":"78","author":"Miesbach","year":"2023","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jtha.2024.07.029_bib49","doi-asserted-by":"crossref","first-page":"5817","DOI":"10.1182\/bloodadvances.2023010723","article-title":"Residual burden of liver disease after HCV clearance in hemophilia: a word of caution in the era of gene therapy","volume":"7","author":"La Mura","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.07.029_bib50","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1007\/s11606-022-07806-9","article-title":"Prevention of hepatitis B reactivation in patients receiving immunosuppressive therapy: a case series and appraisal of society guidelines","volume":"38","author":"Etienne","year":"2023","journal-title":"J\u00a0Gen Intern Med"},{"key":"10.1016\/j.jtha.2024.07.029_bib51","first-page":"559","article-title":"Gene therapy and hemophilia: where do we go from here?","volume":"13","author":"Bolous","year":"2022","journal-title":"J\u00a0Blood Med"},{"key":"10.1016\/j.jtha.2024.07.029_bib52","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1056\/NEJMc2211173","article-title":"Total knee arthroplasty after gene therapy for hemophilia B","volume":"387","author":"Xue","year":"2022","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.029_bib53","doi-asserted-by":"crossref","DOI":"10.1002\/rth2.12531","article-title":"Musculoskeletal ultrasound in hemophilia: results and recommendations from a global survey and consensus meeting","volume":"5","author":"Bakeer","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.029_bib54","article-title":"Improving patient informed consent for haemophilia gene therapy: the case for change","volume":"2","author":"Woollard","year":"2021","journal-title":"Ther Adv Rare Dis"},{"key":"10.1016\/j.jtha.2024.07.029_bib55","doi-asserted-by":"crossref","first-page":"737","DOI":"10.4155\/bio-2022-0081","volume":"14","author":"Loo","year":"2022","journal-title":"Bioanalysis"},{"issue":"Suppl 1","key":"10.1016\/j.jtha.2024.07.029_bib56","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/ijlh.12352","article-title":"Pearls and pitfalls in factor inhibitor assays","volume":"37","author":"Adcock","year":"2015","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2024.07.029_bib57","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1111\/jth.15281","article-title":"Factor IX assay discrepancies in the setting of liver gene therapy using a hyperfunctional variant factor IX-Padua","volume":"19","author":"Robinson","year":"2021","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.029_bib58","article-title":"Hyperactivity of factor IX Padua (R338L) depends on factor VIIIa cofactor activity","volume":"5","author":"Samelson-Jones","year":"2019","journal-title":"JCI Insight"},{"key":"10.1016\/j.jtha.2024.07.029_bib59","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/hae.12449","article-title":"Recombinant factor IX: discrepancies between one-stage clotting and chromogenic assays","volume":"20","author":"Wilmot","year":"2014","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib60","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/hae.12639","article-title":"Current laboratory practices in the diagnosis and management of haemophilia: a global assessment","volume":"21","author":"Kitchen","year":"2015","journal-title":"Haemophilia"},{"key":"10.1016\/j.jtha.2024.07.029_bib62","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jhep.2023.10.029","article-title":"Adeno-associated viruses for gene therapy - clinical implications and liver-related complications, a guide for hepatologists","volume":"80","author":"M\u00fccke","year":"2024","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jtha.2024.07.029_bib63","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1056\/NEJMoa2211075","article-title":"Two-year outcomes of valoctocogene roxaparvovec therapy for hemophilia A","volume":"388","author":"Mahlangu","year":"2023","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jtha.2024.07.029_bib64","first-page":"887","article-title":"Gene therapy for hemophilia-opportunities and risks","volume":"119","author":"Miesbach","year":"2022","journal-title":"Dtsch \u00c4rztebl Int"},{"key":"10.1016\/j.jtha.2024.07.029_bib65","doi-asserted-by":"crossref","first-page":"4966","DOI":"10.1182\/bloodadvances.2023009876","article-title":"Molecular evaluation and vector integration analysis of HCC complicating AAV gene therapy for hemophilia B","volume":"7","author":"Schmidt","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.jtha.2024.07.029_bib66","doi-asserted-by":"crossref","DOI":"10.3324\/haematol.2023.284622","article-title":"Next-generation strategies to improve safety and efficacy of adeno-associated virus-based gene therapy for hemophilia: lessons from clinical trials in other gene therapies","author":"Di Minno","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.jtha.2024.07.029_bib68","doi-asserted-by":"crossref","first-page":"1510","DOI":"10.1016\/j.jtha.2023.12.039","article-title":"Recommendations for a minimum data set for monitoring gene therapy in hemophilia: communication from the ISTH SSC Working Group on Gene Therapy","volume":"22","author":"Miesbach","year":"2024","journal-title":"J\u00a0Thromb Haemost"},{"key":"10.1016\/j.jtha.2024.07.029_bib69","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.2147\/PPA.S355627","article-title":"The hemophilia gene therapy patient journey: questions and answers for shared decision-making","volume":"16","author":"Wang","year":"2022","journal-title":"Patient Prefer Adherence"},{"key":"10.1016\/j.jtha.2024.07.029_bib70","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1515\/cclm-2018-0174","article-title":"On the complexity of hemostasis and the need for harmonization of test practice","volume":"56","author":"Favaloro","year":"2018","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jtha.2024.07.029_bib71","doi-asserted-by":"crossref","first-page":"105","DOI":"10.11613\/BM.2014.012","article-title":"Harmonization of pre-analytical quality indicators","volume":"24","author":"Plebani","year":"2014","journal-title":"Biochem Med (Zagreb)"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004847?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783624004847?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,18]],"date-time":"2024-12-18T21:37:53Z","timestamp":1734557873000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783624004847"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":68,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S1538783624004847"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.029","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Gene therapy for people with hemophilia B: a proposed care delivery model in Italy","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2024.07.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}